ヘルスケア受託研究機関の市場規模、シェア、動向分析レポート：タイプ別、サービス別、治療領域別、分子別、地域別、セグメント予測、2025年～2030年

ヘルスケア調査受託機関市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のヘルスケア受託研究機関市場規模は2030年までに806億1,000万米ドルに達すると推定され、2025年から2030年にかけてCAGR 7.0%で成長すると予測されています。

医薬品開発コストの増加は、予測期間中の市場需要を促進すると予想されます。また、臨床試験コストの上昇と患者募集に関する課題により、バイオ医薬品企業はコスト削減と迅速な患者募集のために中東欧、アジア太平洋、ラテンアメリカ、中東などの地域に目を向けています。

加えて、業界各社に対する厳しいスケジュール遵守へのプレッシャーの高まりにより、研究活動をCRO（受託研究機関）にアウトソーシングする需要が高まっています。一部の政府機関も、必要なインフラと専門知識で臨床試験を実施し、コストとスケジュールを最小化できるよう、臨床試験活動をアウトソーシングしています。

CRO市場は、パンデミック（世界的大流行）の影響により臨床試験実施施設が閉鎖されるなど、一時的な影響を受けました。しかし、治療に対する大きな需要のため、ウイルスの蔓延を避けるための一定の対策と予防措置を講じた上で、臨床試験サイトは再開されました。さらに、コロナウイルスに対するワクチンの発見に世界的に焦点が当てられていることは、COVID-19に対するワクチン＆薬剤の開発に大きな影響を与えています。これは市場にプラスの影響を与えると予想されます。

過去5年間で、M&Aの件数は大幅に増加しました。2016年以降2023年まで、複数の大型合併が見られます。さらに、2022年3月には、M&B Sciences Inc.がClara Healthを買収し、M&B Sciencesのデジタル技術に基づく臨床試験へのアクセスを拡大したように、大型取引の傾向は2021年以降に活発化しているようです。さらに、2021年12月にはサーモ・フィッシャーが医薬品サービス大手PPDの買収を発表し、2021年2月にはICON plcがPRA Health Sciencesの買収を発表しました。バイオ医薬品・製薬企業のサービス領域で使用される分析技術やソフトウェア・ソリューションの周辺では、統合の時代が到来しています。したがって、前述の要因が市場の成長を支えました。

ヘルスケア受託研究機関市場のレポートハイライト

• タイプ別では、臨床分野が2024年の世界のヘルスケアCRO市場を独占し、76.2%の最大シェアを占めています。これは、臨床分野がヒトを対象とした研究を含む4つの精巧なフェーズで構成されているためです。新たな治療に対する大きな需要が、このセグメントの成長にさらに貢献しています。
• サービスの中では、臨床モニタリング分野が2024年の市場シェアで19.91%と最大でした。
• 北米は2024年に45.50%と大きな市場シェアを占めましたが、これは研究活動に収益の大部分を投資する世界企業が複数存在するためです。
• アジア太平洋地域のヘルスケアCRO市場は、予測期間中に最も速いCAGRで成長すると予想されています。
• 中国、日本、インドは、疾病の蔓延率が高いことから、医薬品受託研究機関市場の著しい成長が予測されます。中国、日本、インドは、疾患有病率の高さにより、医薬品受託研究機関市場で驚異的な成長を示すと予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ヘルスケア受託研究機関（CRO）市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 補助市場の見通し
• 市場力学
  • 市場ドライバー分析
  • 市場抑制要因分析
• 技術の進歩
  • AIとデジタル技術の統合
• スポンサーによるR&D投資の視点
• 臨床試験量分析、2024年
  • 臨床試験の総数　地域別（2024年）
  • 臨床試験の総数　フェーズ別（2024年）
  • 臨床試験の総数　研究デザイン別（2024年）
  • 臨床試験の総数　主要治療領域別（2024年）
• 市場分析ツール
  • ポーターのファイブフォース分析
  • SWOT分析によるPESTEL
  • COVID-19の影響分析

第4章：ヘルスケア受託研究機関（CRO）市場：タイプの推定と動向分析

• セグメントダッシュボード
• 世界のヘルスケア受託研究機関（CRO）市場変動分析
• 世界のヘルスケア受託研究機関（CRO）市場規模と動向分析、タイプ別、2018～2030年
• 創薬
  • 創薬ヘルスケア受託研究機関市場
  • ターゲット検証
  • リードの特定
  • リード最適化
• 前臨床
  • 前臨床ヘルスケア受託研究機関市場
• 臨床
  • 臨床ヘルスケア受託研究機関市場
  • フェーズI試験サービス
  • フェーズII試験サービス
  • フェーズIII試験サービス
  • フェーズIV試験サービス

第5章 ヘルスケア受託研究機関（CRO）市場： サービス推定・動向分析

• セグメントダッシュボード
• 世界のヘルスケア受託研究機関（CRO）市場変動分析
• 世界のヘルスケア受託研究機関（CRO）市場規模と動向分析、サービス別、2018～2030年
• プロジェクト管理/臨床供給管理
  • プロジェクト管理/臨床供給管理ヘルスケア受託研究機関市場
• データ管理
  • データ管理ヘルスケア受託研究機関市場
• 規制/医療関連
  • 規制/医療業務ヘルスケア受託研究機関市場
• メディカルライティング
  • メディカルライティングヘルスケア受託研究機関市場
• 臨床モニタリング
  • 臨床モニタリングヘルスケア受託研究機関市場
• 品質管理/保証
  • 品質管理/保証ヘルスケア受託研究機関市場
• 生物統計学
  • バイオ統計ヘルスケア受託研究機関市場
• 調査員への支払い
  • 研究者への支払いヘルスケア受託研究機関市場
• 研究室
  • ラボヘルスケア受託研究機関市場
  • 無菌試験
  • 容器/閉鎖試験
  • 抽出物および浸出物試験
  • 環境モニタリング
  • 消毒薬の有効性に関する研究
  • その他
• 患者と施設の募集
  • 患者および施設募集ヘルスケア受託研究機関市場
• テクノロジー
  • テクノロジーヘルスケア受託研究機関市場
• その他
  • その他ヘルスケア受託研究機関市場

第6章 ヘルスケア受託研究機関（CRO）市場：治療領域の推定・動向分析

• セグメントダッシュボード
• 世界のヘルスケア受託研究機関（CRO）市場変動分析
• 世界のヘルスケア受託研究機関（CRO）市場規模と動向分析、治療領域別、2018～2030年
• 腫瘍学
• 中枢神経系疾患
• 感染症
• 免疫疾患
• 心血管疾患
• 呼吸器疾患
• 糖尿病
• 眼科
• 疼痛管理
• その他

第7章 ヘルスケア受託研究機関（CRO）市場：分子推定・動向分析

• セグメントダッシュボード
• 世界のヘルスケア受託研究機関（CRO）市場変動分析
• 世界のヘルスケア受託研究機関（CRO）市場規模と動向分析、分子別、2018～2030年
• 医薬品
  • 医薬品ヘルスケア受託研究機関市場
  • 小分子
  • 生物学的製剤
• 医療機器
  • 医療機器ヘルスケア受託研究機関市場

第8章 ヘルスケア受託研究機関（CRO）市場：地域推定・動向分析

• 地域市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模と予測動向分析、2018年～2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
  • スイス
  • ベルギー
  • オランダ
  • オーストリア
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • 台湾
  • インドネシア
  • マレーシア
  • シンガポール
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • コロンビア
  • チリ
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート
  • エジプト
  • イスラエル

第9章 競合情勢

• 市場参入企業の分類
  • マーケットリーダー
  • 新興企業
• 競争市場シェア / 評価分析、2024年
• 企業プロファイル
  • ICON Plc
  • Charles River Laboratories
  • Syneos Health
  • IQVIA Inc.
  • GVK Biosciences Private Limited（Aragen）
  • LabCorp
  • Parexel International Corporation
  • WuXi AppTec
  • Thermo Fisher Scientific Inc.
  • CTI Clinical Trial &Consulting
  • PSI
  • Medpace
  • Ergomed
  • Worldwide Clinical Trials
  • Medidata Solutions, Inc.
  • Pharmaron GMBH
  • SGS SA
  • KCR SA
  • Advanced Clinical Research Services, LLC.
  • Pharm-Olam, LLC（Allucent）

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 4 Global Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 5 Global Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 6 Global Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 7 Global Nucleic Acid Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
• Table 8 North America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 10 North America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 11 North America Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 12 North America Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 13 U.S. Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 15 U.S. Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 16 U.S. Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 17 Canada Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 18 Canada Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 19 Canada Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 20 Canada Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 21 Mexico Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 22 Mexico Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 23 Mexico Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 24 Mexico Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 25 Europe Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
• Table 26 Europe Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 27 Europe Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 28 Europe Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 29 Europe Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 30 Germany Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 31 Germany Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 32 Germany Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 33 Germany Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 34 UK Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 35 UK Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 36 UK Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 37 UK Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 38 France Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 39 France Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 40 France Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 41 France Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 42 Italy Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 43 Italy Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 44 Italy Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 45 Italy Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 46 Spain Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 47 Spain Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 48 Spain Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 49 Spain Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 50 Denmark Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 51 Denmark Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 52 Denmark Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 53 Denmark Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 54 Sweden Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 55 Sweden Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 56 Sweden Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 57 Sweden Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 58 Norway Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 59 Norway Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 60 Norway Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 61 Norway Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 62 Switzerland Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 63 Switzerland Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 64 Switzerland Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 65 Switzerland Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 66 Belgium Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 67 Belgium Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 68 Belgium Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 69 Belgium Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 70 Netherlands Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 71 Netherlands Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 72 Netherlands Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 73 Netherlands Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 74 Austria Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 75 Austria Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 76 Austria Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 77 Austria Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 78 Asia Pacific Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
• Table 79 Asia Pacific Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 80 Asia Pacific Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 81 Asia Pacific Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 82 Asia Pacific Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 83 China Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 84 China Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 85 China Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 86 China Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 87 Japan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 88 Japan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 89 Japan Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 90 Japan Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 91 India Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 92 India Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 93 India Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 94 India Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 95 South Korea Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 96 South Korea Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 97 South Korea Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 98 South Korea Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 99 Australia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 100 Australia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 101 Australia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 102 Australia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 103 Thailand Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 104 Thailand Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 105 Thailand Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 106 Thailand Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 107 Taiwan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 108 Taiwan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 109 Taiwan Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 110 Taiwan Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 111 Indonesia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 112 Indonesia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 113 Indonesia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 114 Indonesia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 115 Malaysia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 116 Malaysia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 117 Malaysia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 118 Malaysia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 119 Singapore Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 120 Singapore Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 121 Singapore Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 122 Singapore Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 123 Latin America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
• Table 124 Latin America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 125 Latin America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 126 Latin America Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 127 Latin America Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 128 Brazil Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 129 Brazil Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 130 Brazil Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 131 Brazil Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 132 Argentina Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 133 Argentina Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 134 Argentina Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 135 Argentina Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 136 Colombia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 137 Colombia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 138 Colombia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 139 Colombia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 140 Chile Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 141 Chile Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 142 Chile Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 143 Chile Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 144 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
• Table 145 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 146 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 147 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 148 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 149 South Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 150 South Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 151 South Africa Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 152 South Africa Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 153 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 154 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 155 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 156 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 157 UAE Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 158 UAE Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 159 UAE Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 160 UAE Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 161 Kuwait Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 162 Kuwait Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 163 Kuwait Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 164 Kuwait Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 165 Egypt Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 166 Egypt Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 167 Egypt Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 168 Egypt Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)
• Table 169 Israel Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
• Table 170 Israel Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
• Table 171 Israel Nucleic Acid Therapeutics CDMO, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 172 Israel Nucleic Acid Therapeutics CDMO, by Molecule, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Healthcare Contract Research Organizations (CRO), Market Segmentation
• Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 Regional Marketplace: Key Takeaways
• Fig. 12 Global Healthcare Contract Research Organizations (CRO), for Drug Discovery, 2018 - 2030 (USD Million)
• Fig. 13 Global Healthcare Contract Research Organizations (CRO), for Target Validation, 2018 - 2030 (USD Million)
• Fig. 14 Global Healthcare Contract Research Organizations (CRO), for Lead Identification, 2018 - 2030 (USD Million)
• Fig. 15 Global Healthcare Contract Research Organizations (CRO), for Lead Optimization, 2018 - 2030 (USD Million)
• Fig. 16 Global Healthcare Contract Research Organizations (CRO), for Pre-Clinical, 2018 - 2030 (USD Million)
• Fig. 17 Global Healthcare Contract Research Organizations (CRO), for Clinical, 2018 - 2030 (USD Million)
• Fig. 18 Global Healthcare Contract Research Organizations (CRO), for Phase I Trials, 2018 - 2030 (USD Million)
• Fig. 19 Global Healthcare Contract Research Organizations (CRO), for Phase II Trials, 2018 - 2030 (USD Million)
• Fig. 20 Global Healthcare Contract Research Organizations (CRO), for Phase III Trials, 2018 - 2030 (USD Million)
• Fig. 21 Global Healthcare Contract Research Organizations (CRO), for Phase IV Trials, 2018 - 2030 (USD Million)
• Fig. 22 Global Healthcare Contract Research Organizations (CRO), for Project Management/Clinical Supply Management, 2018 - 2030 (USD Million)
• Fig. 23 Global Healthcare Contract Research Organizations (CRO), for Data Management, 2018 - 2030 (USD Million)
• Fig. 24 Global Healthcare Contract Research Organizations (CRO), for Regulatory/Medical Affairs, 2018 - 2030 (USD Million)
• Fig. 25 Global Healthcare Contract Research Organizations (CRO), for Medical Writing, 2018 - 2030 (USD Million)
• Fig. 26 Global Healthcare Contract Research Organizations (CRO), for Clinical Monitoring, 2018 - 2030 (USD Million)
• Fig. 27 Global Healthcare Contract Research Organizations (CRO), for Quality Management/ Assurance, 2018 - 2030 (USD Million)
• Fig. 28 Global Healthcare Contract Research Organizations (CRO), for Bio-statistics, 2018 - 2030 (USD Million)
• Fig. 29 Global Healthcare Contract Research Organizations (CRO), for Investigator Payments , 2018 - 2030 (USD Million)
• Fig. 30 Global Healthcare Contract Research Organizations (CRO), for Laboratory, 2018 - 2030 (USD Million)
• Fig. 31 Global Healthcare Contract Research Organizations (CRO), for Sterility Testing, 2018 - 2030 (USD Million)
• Fig. 32 Global Healthcare Contract Research Organizations (CRO), for Container/Closure Testing, 2018 - 2030 (USD Million)
• Fig. 33 Global Healthcare Contract Research Organizations (CRO), for Extractables and Leachable Testing, 2018 - 2030 (USD Million)
• Fig. 34 Global Healthcare Contract Research Organizations (CRO), for Environmental Monitoring (Including Microbiology Testing), 2018 - 2030 (USD Million)
• Fig. 35 Global Healthcare Contract Research Organizations (CRO), for Disinfectant Efficacy Studies, 2018 - 2030 (USD Million)
• Fig. 36 Global Healthcare Contract Research Organizations (CRO), for Others, 2018 - 2030 (USD Million)
• Fig. 37 Global Healthcare Contract Research Organizations (CRO), for Patient and Site Recruitment , 2018 - 2030 (USD Million)
• Fig. 38 Global Healthcare Contract Research Organizations (CRO), for Technology , 2018 - 2030 (USD Million)
• Fig. 39 Global Healthcare Contract Research Organizations (CRO), for Others, 2018 - 2030 (USD Million)
• Fig. 40 Global Healthcare Contract Research Organizations (CRO), for Oncology , 2018 - 2030 (USD Million)
• Fig. 41 Global Healthcare Contract Research Organizations (CRO), for CNS Disorders , 2018 - 2030 (USD Million)
• Fig. 42 Global Healthcare Contract Research Organizations (CRO), for Infectious Diseases , 2018 - 2030 (USD Million)
• Fig. 43 Global Healthcare Contract Research Organizations (CRO), for Immunological Disorders , 2018 - 2030 (USD Million)
• Fig. 44 Global Healthcare Contract Research Organizations (CRO), for Cardiovascular Diseases, 2018 - 2030 (USD Million)
• Fig. 45 Global Healthcare Contract Research Organizations (CRO), for Respiratory Diseases , 2018 - 2030 (USD Million)
• Fig. 46 Global Healthcare Contract Research Organizations (CRO), for Diabetes , 2018 - 2030 (USD Million)
• Fig. 47 Global Healthcare Contract Research Organizations (CRO), for Ophthalmology , 2018 - 2030 (USD Million)
• Fig. 48 Global Healthcare Contract Research Organizations (CRO), for Pain Management, 2018 - 2030 (USD Million)
• Fig. 49 Global Healthcare Contract Research Organizations (CRO), for Others, 2018 - 2030 (USD Million)
• Fig. 50 Global Healthcare Contract Research Organizations (CRO), for Pharmaceuticals, 2018 - 2030 (USD Million)
• Fig. 51 Global Healthcare Contract Research Organizations (CRO), for Small Molecules, 2018 - 2030 (USD Million)
• Fig. 52 Global Healthcare Contract Research Organizations (CRO), for Biologics, 2018 - 2030 (USD Million)
• Fig. 53 Global Healthcare Contract Research Organizations (CRO), for Medical Device, 2018 - 2030 (USD Million)
• Fig. 54 Regional Outlook, 2024 & 2030
• Fig. 55 North America Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 56 US Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Canada Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Mexico Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Europe Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 60 UK Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Germany Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 62 France Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Italy Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Spain Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Denmark Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Sweden Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Norway Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Switzerland Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Belgium Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Netherlands Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Austria Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Asia Pacific Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 73 India Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 74 China Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Japan Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 76 South Korea Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Australia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Thailand Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Taiwan Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Indonesia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Malaysia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Singapore Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Latin America Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Brazil Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Argentina Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Colombia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Chile Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 88 MEA Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 89 South Africa Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Saudi Arabia Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 91 UAE Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Kuwait Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Egypt Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Israel Healthcare Contract Research Organizations (CRO) Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Healthcare Contract Research Organization Market Growth & Trends:

The global healthcare contract research organization market size is estimated to reach USD 80.61 billion by 2030, registering to grow at a CAGR of 7.0% from 2025 to 2030 according to a new report by Grand View Research, Inc. The increasing cost of drug development is expected to drive market demand over the forecast period. Also, rising clinical trials cost and challenges pertaining to patient recruitment have led biopharmaceutical companies to turn to regions like Central and Eastern Europe, Asia Pacific, Latin America, and the Middle East for cost savings and quick patient recruitment.

In addition, growing pressure on industry players to follow stringent timelines has increased the demand for outsourcing research activities to contract research organizations (CROs). Some government organizations are also outsourcing their clinical trial activities so that they can carry out clinical trials with the required infrastructure and expertise and minimize their cost and timelines.

The CRO market was temporarily affected by the ongoing pandemic, as it led to the closure of clinical trial sites. However, owing to the significant demand for treatments, the clinical trial sites were reopened with certain measures and precautions to avoid the spread of the virus. Moreover, the worldwide focus on finding a vaccine against coronavirus has had a significant impact on the development of vaccines & drugs for COVID-19. This is expected to have a positive impact on the market.

Over the past 5 years, the number of mergers and acquisitions significantly increased. Several large mergers have been witnessed since 2016 till 2023. Moreover, the trend of large transactions seems to be picking up since 2021, as in March 2022, M&B Sciences Inc, acquired Clara Health, which expanded M&B Sciences' access to digital technology-based clinical trials. Moreover, in December 2021, Thermo Fisher announced the acquisition of pharmaceutical services giant PPD, and in February 2021, ICON plc announced the acquisition of PRA Health Sciences. An era of consolidation has been witnessed around analytical technologies and software solutions used in the biopharmaceutical and pharmaceutical companies' services space. Hence, the aforementioned factors supported the market's growth.

Healthcare Contract Research Organization Market Report Highlights:

• Based on type, the clinical segment has dominated the global healthcare CRO market in 2024, with the largest share of 76.2% owing to the fact that it comprises four elaborate phases, including human subjects. The significant demand for new treatments has further contributed to the growth of the segment.
• Among services, the clinical monitoring segment was the largest in terms of market share at 19.91% in 2024.
• North America held a significant market share of 45.50% in 2024 due to the presence of several global players who invest a major part of their revenue in research activities.
• The healthcare Contract Research Organizations market in Asia Pacific is expected to grow at the fastest CAGR over the forecast period.
• China, Japan, and India are projected to witness tremendous growth in the contract research organization market owing to high disease prevalence. China, Japan, and India are projected to witness tremendous growth in the contract research organization market owing to high disease prevalence.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Healthcare Contract Research Organizations (CRO) Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Rate of Clinical Research To Boost Demand For Outsourcing Services
    • 3.2.1.2. Increasing Adoption Of Advanced Technologies
    • 3.2.1.3. Increasing Mergers and Collaborations
    • 3.2.1.4. Increasing Demand For Outsourcing Services Across The Developing Economies
    • 3.2.1.5. Patent Cliff
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality issues of CRO services
    • 3.2.2.2. Intellectual property rights issues
• 3.3. Technological Advancements
  • 3.3.1. Integration of AI and digital technologies
• 3.4. R&D Investment Perspective, by Sponsors
• 3.5. Clinical Trials Volume Analysis, 2024
  • 3.5.1. Total Number of Clinical Trials, by Region (2024)
  • 3.5.2. Total Number of Clinical Trials, by Phase (2024)
  • 3.5.3. Total Number of Clinical Trials, by Study Design (2024)
  • 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Healthcare Contract Research Organizations (CRO) Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 4.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
• 4.4. Drug Discovery
  • 4.4.1. Drug Discovery Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.4.2. Target Validation
    • 4.4.2.1. Target Validation Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.4.3. Lead Identification
    • 4.4.3.1. Lead Identification Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.4.4. Lead Optimization
    • 4.4.4.1. Lead Optimization Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 4.5. Pre-clinical
  • 4.5.1. Pre-clinical Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 4.6. Clinical
  • 4.6.1. Clinical Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.2. Phase I Trial Services
    • 4.6.2.1. Phase I Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.3. Phase II Trial Services
    • 4.6.3.1. Phase II Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.4. Phase III Trial Services
    • 4.6.4.1. Phase III Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 4.6.5. Phase IV Trial Services
    • 4.6.5.1. Phase IV Trial Services Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 5. Healthcare Contract Research Organizations (CRO) Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 5.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Service, 2018 - 2030 (USD Million)
• 5.4. Project Management/Clinical Supply Management
  • 5.4.1. Project Management/Clinical Supply Management Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.5. Data Management
  • 5.5.1. Data Management Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.6. Regulatory/Medical Affairs
  • 5.6.1. Regulatory/Medical Affairs Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.7. Medical Writing
  • 5.7.1. Medical Writing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.8. Clinical Monitoring
  • 5.8.1. Clinical Monitoring Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.9. Quality Management/Assurance
  • 5.9.1. Quality Management/Assurance Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.10. Bio-statistics
  • 5.10.1. Bio-statistics Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.11. Investigator Payments
  • 5.11.1. Investigator Payments Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.12. Laboratory
  • 5.12.1. Laboratory Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.2. Sterility Testing
    • 5.12.2.1. Sterility Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.3. Container/Closure Testing
    • 5.12.3.1. Container/Closure Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.4. Extractables and Leachable Testing
    • 5.12.4.1. Extractables and Leachable Testing Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.5. Environmental Monitoring
    • 5.12.5.1. Environmental Monitoring Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.6. Disinfectant Efficacy Studies
    • 5.12.6.1. Disinfectant Efficacy Studies Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 5.12.7. Others
    • 5.12.7.1. Others Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.13. Patient and Site Recruitment
  • 5.13.1. Patient and Site Recruitment Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.14. Technology
  • 5.14.1. Technology Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 5.15. Others
  • 5.15.1. Others Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 6. Healthcare Contract Research Organizations (CRO) Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 6.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. CNS Disorders
  • 6.5.1. CNS Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Infectious Diseases
  • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Immunological Disorders
  • 6.7.1. Immunological Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Cardiovascular Diseases
  • 6.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.9. Respiratory Diseases
  • 6.9.1. Respiratory Diseases Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.10. Diabetes
  • 6.10.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.11. Ophthalmology
  • 6.11.1. Ophthalmology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.12. Pain Management
  • 6.12.1. Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.13. Others
  • 6.13.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Healthcare Contract Research Organizations (CRO) Market: Molecule Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Healthcare Contract Research Organizations (CRO) Market Movement Analysis
• 7.3. Global Healthcare Contract Research Organizations (CRO) Market Size & Trend Analysis, by Molecule, 2018 - 2030 (USD Million)
• 7.4. Pharmaceuticals
  • 7.4.1. Pharmaceuticals Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 7.4.2. Small Molecules
    • 7.4.2.1. Small Molecules Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
  • 7.4.3. Biologics
    • 7.4.3.1. Biologics Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)
• 7.5. Medical Device
  • 7.5.1. Medical Device Healthcare Contract Research Organization Market, 2018 - 2030 (USD Million)

Chapter 8. Healthcare Contract Research Organizations (CRO) Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Global Regional Market Snapshot
• 8.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.10. Switzerland
    • 8.5.10.1. Key Country Dynamics
    • 8.5.10.2. Competitive Scenario
    • 8.5.10.3. Regulatory Framework
    • 8.5.10.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.11. Belgium
    • 8.5.11.1. Key Country Dynamics
    • 8.5.11.2. Competitive Scenario
    • 8.5.11.3. Regulatory Framework
    • 8.5.11.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.12. Netherlands
    • 8.5.12.1. Key Country Dynamics
    • 8.5.12.2. Competitive Scenario
    • 8.5.12.3. Regulatory Framework
    • 8.5.12.4. Netherlands Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.13. Austria
    • 8.5.13.1. Key Country Dynamics
    • 8.5.13.2. Competitive Scenario
    • 8.5.13.3. Regulatory Framework
    • 8.5.13.4. Austria Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Japan
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.8. Taiwan
    • 8.6.8.1. Key Country Dynamics
    • 8.6.8.2. Competitive Scenario
    • 8.6.8.3. Regulatory Framework
    • 8.6.8.4. Taiwan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.9. Indonesia
    • 8.6.9.1. Key Country Dynamics
    • 8.6.9.2. Competitive Scenario
    • 8.6.9.3. Regulatory Framework
    • 8.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.10. Malaysia
    • 8.6.10.1. Key Country Dynamics
    • 8.6.10.2. Competitive Scenario
    • 8.6.10.3. Regulatory Framework
    • 8.6.10.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.11. Singapore
    • 8.6.11.1. Key Country Dynamics
    • 8.6.11.2. Competitive Scenario
    • 8.6.11.3. Regulatory Framework
    • 8.6.11.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. Colombia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.5. Chile
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.6. Egypt
    • 8.8.6.1. Key Country Dynamics
    • 8.8.6.2. Competitive Scenario
    • 8.8.6.3. Regulatory Framework
    • 8.8.6.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.7. Israel
    • 8.8.7.1. Key Country Dynamics
    • 8.8.7.2. Competitive Scenario
    • 8.8.7.3. Regulatory Framework
    • 8.8.7.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Competitive Market Share/Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. ICON Plc
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Charles River Laboratories
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Syneos Health
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. IQVIA Inc.
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. GVK Biosciences Private Limited (Aragen)
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. LabCorp
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Parexel International Corporation
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. WuXi AppTec
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Thermo Fisher Scientific Inc.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. CTI Clinical Trial & Consulting
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. PSI
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Medpace
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Ergomed
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Worldwide Clinical Trials
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Medidata Solutions, Inc.
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives
  • 9.3.16. Pharmaron GMBH
    • 9.3.16.1. Company Overview
    • 9.3.16.2. Financial Performance
    • 9.3.16.3. Service Benchmarking
    • 9.3.16.4. Strategic Initiatives
  • 9.3.17. SGS SA
    • 9.3.17.1. Company Overview
    • 9.3.17.2. Financial Performance
    • 9.3.17.3. Service Benchmarking
    • 9.3.17.4. Strategic Initiatives
  • 9.3.18. KCR S.A.
    • 9.3.18.1. Company Overview
    • 9.3.18.2. Financial Performance
    • 9.3.18.3. Service Benchmarking
    • 9.3.18.4. Strategic Initiatives
  • 9.3.19. Advanced Clinical Research Services, LLC.
    • 9.3.19.1. Company Overview
    • 9.3.19.2. Financial Performance
    • 9.3.19.3. Service Benchmarking
    • 9.3.19.4. Strategic Initiatives
  • 9.3.20. Pharm-Olam, LLC (Allucent)
    • 9.3.20.1. Company Overview
    • 9.3.20.2. Financial Performance
    • 9.3.20.3. Service Benchmarking
    • 9.3.20.4. Strategic Initiatives